Back to search

University of Sheffield

Interactions between aspirin and P2Y12 receptor antagonists in ischaemic heart disease

Abstract

dc:description.abstract

A combination of aspirin 75 mg once daily (OD) and the P2Y12 inhibitor ticagrelor represents the current standard antiplatelet treatment for acute coronary syndromes (ACS). Prolonged therapy is indicated in patients at high risk of ischaemic events but low risk of bleeding, though varying aspirin dose and frequency of administration may modulate its actions and consistency of effect. Daily doses of aspirin <75 mg may exert significant effect and twice-daily (BD) administration may improve consistency, but these regimens have not been studied in those receiving ticagrelor. Aspirin potentiates certain pathways of inflammation that may hypothetically drive atherogenesis and be counteractive in atherothrombosis. This project characterised a novel regimen of very-low-dose BD aspirin, when given alone and in combination with ticagrelor, compared to standard regimens of aspirin and DAPT.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Parker, William
Advisor dc:contributor.advisor
  • Storey, Robert
ORCID person:identifier.orcid

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.826827
Dc Identifier Grantnumber
X/005998-31-9
FS/18/49/33752
192006

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Parker, William. Interactions between aspirin and P2Y12 receptor antagonists in ischaemic heart disease. doctoral thesis, University of Sheffield, 2020.